AMCP Conference Panelists Decry ‘Innovation Reduction Act’
-
Apr 04, 2025
The “well-intentioned” Inflation Reduction Act (IRA) of 2022 could cause more harm than good in the world of payers, pharmacies and drug development, according to experts who spoke at the 2025 Academy of Managed Care Pharmacy conference in Houston, held March 31 through April 3.
The IRA introduced a $2,000 cap on Medicare Part D beneficiaries’ out-of-pocket drug costs in the catastrophic phase of coverage, which took effect this year. When the cap is met, the remaining cost responsibility is shouldered by payers and drug manufacturers, which both are now paying a larger share of those costs than they did before the IRA.
Read more
© 2025 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.